Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PD-1 Inhibitor Bests Chemo for Colorectal Cancer

1 Jun 2020

Abstract excerpt

Findings from the KEYNOTE-177 study indicate that pembrolizumab is superior to the current standard of care, significantly improving progression-free survival when deployed up front to treat patients with metastatic DNA mismatch repair/microsatellite instability-high colorectal cancer.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Colorectal Cancer Treatments and Studies
Share to Genetic factors in colorectal cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32482631
DOI: 10.1158/2159-8290.cd-nb2020-051

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PD-1 Inhibitor Bests Chemo for Colorectal CancerPMID 32482631Read ↗

Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase III KEYNOTE-177 studySemantic proximity Read ↗

Pembrolizumab in Asian patients with microsatellite‐instability‐high/mismatch‐repair‐deficient colorectal cancerSemantic proximity Read ↗

Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trialSemantic proximity Read ↗

Pembrolizumab in MSI-H–dMMR Advanced Colorectal Cancer — A New Standard of CareSemantic proximity Read ↗

From poor prognosis to precision promise: Clinical trials targeting BRAF-mutant metastatic colorectal cancer.Semantic proximity Read ↗

Dual-immunotherapy triumphs: redefining deficient mismatch repair or high microsatellite instability metastatic colorectal cancer first-line treatmentSemantic proximity Read ↗

Promising New Agents for Colorectal Cancer.Semantic proximity Read ↗

Pucotenlimab in patients with advanced mismatch repair-deficient or microsatellite instability-high solid tumors: A multicenter phase 2 studySemantic proximity Read ↗

The Efficacy and Safety of Pembrolizumab, Ipilimumab, and Nivolumab Monoteraphy and Combination for Colorectal Cancer: A Systematic Review and Meta-AnalysisSemantic proximity Read ↗

Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 studySemantic proximity Read ↗

Clinical research progress on BRAF V600E-mutant advanced colorectal cancer.Semantic proximity Read ↗

Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.